SynthesisMedicine2015
Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis.
Synthesis in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 8 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.Medicine · 2020Pooled it
- Pooled it
- The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.BMC cancer · 2017Pooled it
- PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Scientific reports · 2017Pooled it
- Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.Oncotarget · 2017Pooled it
- Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis.Pathology oncology research : POR · 2016Pooled it
- PD-L1 and Survival in Solid Tumors: A Meta-Analysis.PloS one · 2015Pooled it
- PD-L1 Expression and Immune Microenvironment Remodeling During Laryngeal Carcinogenesis: Implications for Malignant Progression of Laryngeal Dysplasia.International journal of molecular sciences · 2026Article
- Survival Impact of Programmed Cell Death Ligand-1 Expression in Patients With Epithelial Ovarian Carcinoma.Cancer reports (Hoboken, N.J.) · 2026Article
- Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) tumour expression in gastric carcinoma.The Indian journal of medical research · 2025Article
- Circulating stem-like exhausted CD8 T cells point to better outcomes in lung cancer: a brief report.Translational lung cancer research · 2025Article
- BPIFB1, Serving as a Downstream Effector of EBV-miR-BART4, Blocks Immune Escape of Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.Biochemical genetics · 2025Article
- The Frequency of PD-L1 Marker Expression in ER Positive, PR Positive, HER2 Negative Invasive Breast Carcinomas, and Its Correlation with Clinicopathological Factors Affecting Prognosis.Advanced biomedical research · 2025Article
- From trash to treasure: tumor draining lymph nodes as a multi-omics goldmine in cancer therapy.Frontiers in oncology · 2025Review
- Investigation of Programmed Death Ligand-1 as a New Prognostic Biomarker in Pancreatic Cancer Patients.ACS pharmacology & translational science · 2024Article
- Stem-like exhausted CD8 T cells in pleural effusions predict improved survival in non-small cell lung cancer (NSCLC) and mesothelioma.Translational lung cancer research · 2024Article
- Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs.Dermatology practical & conceptual · 2024Article
- Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.Cancer reports (Hoboken, N.J.) · 2024Article
- The interplay between programmed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) genotypes in cervical carcinomas: findings of a Nigerian Tertiary Hospital.The Pan African medical journal · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) has been observed in various epithelial-originated malignancies. However, whether the expression of PD-L1 on tumor cells or the expression of PD-1 on tumor-infiltrating lymphocytes (TILs) is associated with patients' survival remains controversial.Electronic databases were searched for eligible literatures. Data of hazard ratio (HR) for overall survival (OS) with 95% confidence interval (CI) according to the expression status of PD-L1 or PD-1 evaluated by immunohistochemistry were extracted. The outcomes were synthesized based on random-effects model. Subgroup analyses were proposed.Twenty-nine studies covering 12 types of epithelial-originated malignancies involving 7319 patients (2030/3641 cases for PD-L1 positive/negative, 505/1143 cases for PD-1 positive/negative) with available data of the outcome stratified by PD-L1/PD-1 status were enrolled. Epithelial-originated cancer patients with positive expression of PD-L1 on tumor tissues were associated with significantly poorer OS when compared to those with negative expression of PD-L1 (HR 1.81, 95% CI 1.33-2.46, P < 0.001). Similarly, patients with PD-1 positive expression on TILs had significantly shorter OS than the PD-1 negative group (HR 2.53, 95% CI 1.22-5.21, P = 0.012). In analyses of PD-L1, all subgroups showed consistent trends toward unfavorable prognoses of patients with positive PD-L1 expression, regardless of antibodies and evaluation cutoffs. Subgroup analyses on PD-1 were not available due to limited data.PD-L1 or PD-1 expression status is a significant prognostic factor in epithelial-originated malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.